IPSC Stock Analysis: Buy, Sell, or Hold?
IPSC - Century Therapeutics, Inc. Common Stock
$2.02
-0.17 (-7.76%)
▼
5d:
-4.27%
30d:
-15.48%
90d:
-11.79%
HOLD
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 13, 2026
9d
Get Alerted When IPSC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: IPSC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: IPSC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: IPSC is currently trading at $2.02, which is considered oversold relative to its 30-day fair value range of $2.14 to $2.38.
Technical Outlook: Technically, IPSC is in a downtrend. The price is currently testing key support at $1.96. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.8% recently.
Market Sentiment: IPSC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.75 (+135.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IPSC is in a downtrend. The price is currently testing key support at $1.96. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.8% recently.
Market Sentiment: IPSC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.75 (+135.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.14 -
$2.38
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.8%)
- BULLISH: Trading 135.1% below Wall St target ($4.75)
Trading Range Analysis
30-Day Trading Range
$2.14 -
$2.38
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.96
Resistance Level
$2.30
Current Trend
Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.42
Wall Street Target
$4.75
(+135.1%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 03, 2026 3:05 AM ET
Data refreshes hourly during market hours. Next update: 4:05 AM
Data refreshes hourly during market hours. Next update: 4:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IPSC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Gregory Russotti
SELL
10076 shares
2026-03-12
Douglas Carr
SELL
7043 shares
2026-03-12
Gregory Russotti
SELL
479 shares
2026-03-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
